investigator-initiated trial, the primary objective was to determine whether there was a progression-free survival (PFS) benefit to switching endocrine therapy (ET; fulvestrant or exemestane) combined with the cyclin-dependent kinase 4/6 inhibitor (CDK4/6...
[14]Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, ...
[4]. Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, et al. The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. Cell Rep. 2018;22(11):2978-94.[5]. Goel S, DeCristo MJ, Watt...
对于存在这样的差异,考虑可能原因如下:第一,不同CDK4/6抑制剂在药物作用机制上还是有所差异的,阿贝西利对CDK4的抑制比对CDK6的抑制能力更强,而哌柏西利则对两者的抑制强度相当,并且阿贝西利对CDK9也有一定的抑制作用[53]。药物作用机制的不同是否会带来疗效和...
CDK inhibitorthrombosisvenousPurpose: Cyclin dependent kinase (CDK) 4/6 inhibitors are integral treatment for advanced hormone receptor positive breast cancer, however venous thromboembolic events (VTE) occurred in 1-5% of clinical trial patients. Thrombosis rates in the real-world setting remain ...
[11]Yap YS, Chiu J, Ito Y, et al. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer. Cancer Sci. 2020;111(9):3313-3326. [12] NCCN Clinical Practice Guid...
Treatment selection after disease progression on a CDK4/6 inhibitor remains an area of active research and is likely to be influenced by the underlying mechanisms of resistance to check access.
而对于中国HR+/HER2-乳腺癌患者来说,由于其发病年龄较年轻,因此中国临床上也更关注CDK4/6抑制剂在年轻乳腺癌患者中的表现。2024 ESMO年会公布的NATALEE研究年轻亚组的分析数据给了我们一个答案,结果提示<40岁患者从瑞波西利辅助强化治疗中...
Fig. 2 Distribution of AE of CDK4/6 inhibitorin different systemic organs NPT represented the number of PTs that generate a signal under the ROR combined with MHRA method; ROR025...
[3]Wander SA, Han HS, Zangardi ML, et al. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw. 2021 Mar 24:1-8. [4]...